NCT07368049Not yet recruiting
MR 7700 Multinuclear Application Clinical Study
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
The purpose of this clinical study is to perform phosphorus nucleus (31P) and sodium nucleus (23Na) imaging of the liver in patients with primary hepatocellular carcinoma (HCC) and healthy volunteers using the MR 7700 Magnetic Resonance Equipment, in order to explore the manifestations of multinuclear imaging in HCC patients and healthy volunteers.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 24 Nov 2025
- Start date
- 5 Jan 2026
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07368049
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 5 Jan 2026 to the primary completion date, 30 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HCC patient group and healthy control group
- Patients with claustrophobia.
- Subject's body temperature \> 39.5°C on the day of scanning.
- Females who plan to be pregnant within 6 months, and pregnant and lactating females.
- Patients with other implants, prostheses, foreign bodies, patches, etc. that are not suitable for MRI examination; patients with electronic implants, such as pacemakers, stimulators, insulin pumps, cochlear implants, etc.
- Critically ill subjects with various resuscitation devices or those with any emergency medical condition requiring first aid.
- Subjects with poor compliance are considered to be excluded by the investigators.
- Subjects who are not considered suitable for this trial by the investigators.
Who the study is looking for
- 1\. HCC patient group
- Age ≥ 18 years;
- With clear consciousness, ability to cooperate, and autonomous behavior;
- Voluntary agreement to participate in this clinical trial and signing of the subject's informed consent form;
- Patients diagnosed with primary hepatocellular carcinoma by imaging or clinical diagnosis, and who have not received tumor treatment.
- 2\. Healthy control group
- Age ≥ 18 years;
- With clear consciousness, ability to cooperate, and autonomous behavior;
- Voluntary agreement to participate in this clinical trial and signing of the subject's informed consent form;
- No previous history of liver disease.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.